Status:
TERMINATED
Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease
Lead Sponsor:
Catharina Ziekenhuis Eindhoven
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (\> 1) short (focal; \> 1 and ...
Eligibility Criteria
Inclusion
- PAOD (ABI \<0.90 and/or a decline of \>0.15 after exercise test), Rutherford category 2, 3 or 4
- Multiple (\>1) short (focal; \>1 and \< 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery
- Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines
- Unilateral occlusive disease
- Age ≥ 18
Exclusion
- Patients with PAOD Rutherford category 5 and 6
- Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat
- Bilateral lesions with treatment indication
- Contra-indication for anticoagulant therapy
- Renal insufficiency (MDRD \< 50 ml/min)
- Life expectancy \< 6 months
- Known contrast allergy
- Pregnancy
- Unable to complete a questionnaire in the home language
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03227822
Start Date
July 1 2013
End Date
February 1 2015
Last Update
October 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.